Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA approves BTG Plc's Varithena for treatment of patients


Tuesday, 26 Nov 2013 05:44am EST 

BTG Plc:Says the US Food and Drug Administration (FDA) has approved Varithena (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system. 

Company Quote

630.0
19.0 +3.11%
11 Jul 2014